The leading assignee in this dataset holds 49 of the 590 records in scope, with a noticeable drop to 25 records at fifth place and 13 at tenth. That gap suggests one organisation has built a materially larger position than the rest of the field, but the top ten together still only account for 45.4% of all records, leaving substantial ground held by a long tail of smaller filers. Anyone assessing competitive exposure should look at both the leader's portfolio and the mid-tier filers, since the field is concentrated but not monopolised.

Filing activity peaked at 24 records in 2018 and has not returned to that level since, with the 2022 midpoint sitting at 20 records and a marked decline shown in the most recent, still-incomplete year. This pattern reads as flat-to-declining rather than growing. Because publication typically lags filing by around 18 months, the very last year of data will revise upward, but the multi-year trend through the midpoint does not indicate an expanding field.

C12N, covering microorganisms and genetic engineering, appears on 89.3% of the 590 records in scope, making it by far the most heavily claimed class. C12P (fermentation and enzymatic synthesis) follows at 51.4%, and C07K (peptides and proteins) at 44.2%. Downstream classes tied to therapeutic use, such as A61K and A61P, appear on a much smaller share of records, indicating that most patent activity centres on host-organism engineering and production processes rather than final therapeutic formulation.

The IPC composition shows several classes with comparatively low record share against the corpus, including C12Q (measuring and testing, 5.4%) and A01K (animal husbandry, 4.7%), which point to less-claimed sub-areas such as enzymatic titer assays and transgenic animal expression hosts. Low record share is not proof of patentability, but it does indicate lighter prior-art density than the crowded C12N and C12P classes. A prudent approach is to draft claims that sit at the intersection of a crowded core class and one of these lighter-claimed branches, rather than filing squarely inside C12N alone.

Moderately concentrated: the top five assignees together hold 29.7% of the 590 records in scope, and the top ten hold 45.4%. That leaves more than half the field spread across the remaining ranked assignees, which is not the profile of a field dominated by two or three players. Recent-year momentum data also shows several previously active leaders posting zero filings in the latest year, suggesting the current concentration reflects historical filing rather than an actively widening lead.